Kidney disease (autosomal dominant polycystic) - tolvaptan [ID652]: committee papers

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology company - Otsuka

03 - Patient Access Scheme submission from the company

04 - NICE request to the manufacturer for clarification on their submission

05 - Manufacturer clarification response

06 - Consultee submission - PKD Charity

07 - Consultee submission - Renal Association

08 - Consultee submission - Royal College of Pathologists

09 - Clinical expert personal perspective - Ong

10 - Clinical expert personal perspective - Hendry

11 - Patient expert personal perspective - Goren

12 - Patient expert personal perspective - Williams

13 - Evidence Review Group report prepared by Kleijnen Systematic Reviews

14 - Evidence Review Group addendum report prepared by Kleijnen Systematic Reviews

15 - Manufacturer factual accuracy check of Evidence Review Group report

16 - Evidence Review Group erratum report prepared by Kleijnen Systematic Reviews

This page was last updated: 03 June 2015